Post-transplant Diabetes Mellitus Clinical Trial
Official title:
GLP-1 Restores Altered Insulin and Glucagon Secretion in Post-transplantation Diabetes Mellitus
Post-transplantation diabetes mellitus (PTDM) develops in 10-15 % of all renal transplant
recipients within 10 weeks after transplantation, and has been associated with increased
risk of cardiovascular disease and impaired patient survival. PTDM is primarily believed to
be a variant of type 2 diabetes mellitus (T2DM), but the pathophysiology underlying the
impaired glucose metabolism in renal transplant recipients with PTDM is unclear and some
aspects are still poorly investigated. Hyperglycemic clamp investigations with concomitant
infusion of glucagon-like peptide-1 (GLP-1) are warranted for a thorough characterization of
the α-cell and β-cell function.
The primary objective of the present study is to investigate whether hyperglucagonemia is
present in renal transplant recipients with PTDM. Furthermore, the investigators aim to
examine the insulinotropic and glucagon suppressive effects of GLP-1 (compared to placebo)
in PTDM patients during fasting glycemia and during hyperglycemic conditions (hyperglycemic
clamp), respectively.
n/a
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04965935 -
Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients
|
Phase 3 | |
| Completed |
NCT05240274 -
The POWERED Study: Prophylaxis With Metformin to Prevent PTDM
|
Phase 2 |